Epidemiology and Outcome of Anaphylactic Shocks Admitted to Intensive Care Unit

Epidemiology and Outcome of Anaphylactic Shocks Admitted to Intensive Care Unit: a French Retrospective Multicenter Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04290507

Acronym

ANAPHYLASHOCK

Enrollment

339

Registered

2020-03-02

Start date

2017-01-01

Completion date

2019-12-31

Last updated

2020-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaphylaxis

Keywords

fluid management, mortality

Brief summary

Anaphylaxis is a severe life-threatening reaction following exposure to an antigen. Its incidence is progressively increasing in the general population over years, accompanied with an increased number of hospitalizations. Although rare, this condition is often associated with a significant morbidity and mortality. The mortality rate has been recently estimated at 0.84 (95% CI, 0.79 to 0.88) per million per year in the French adult population. Age, chronic medication and cardiac or pulmonary comorbidities have been reported to increase the risk of a severe reaction. Obesity, age and cardiovascular comorbidities have been identified as risk factors for fatal anaphylaxis. However, the risk factors for death after ICU admission have not been elucidated yet.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Being \> 18 years old * suffered an anaphylactic reaction, regardless of the location or causative allergen * transferred alive in an ICU

Exclusion criteria

* dead within less than one hour after admission

Design outcomes

Primary

Measure	Time frame	Description
In-ICU mortality	Day 30	The number of participants deceased within ICU hospitalisation

Secondary

Measure	Time frame	Description
Volume of fluid administered	Day 30	The volume of fluid administered during priori to and during ICU stay, in millilitres will be noted
Amount of epinephrine	Day 30	Quantity of epinephrine administered during ICU stay
Amount of norepinephrine	Day 30	Quantity of norepinephrine administered during ICU stay
Number and severity of organ failure	Day 30	The severity of organ failure will be assessed with the SOFA score
Extracorporeal life support requirement	Day 30	The number of participants that required ECMO V/V or A/V

Countries

France

Outcome results